Cancer Immunotherapy: The Role of Mediators
Author Information
Author(s): S. Ben-Efraim
Primary Institution: Sackler Faculty of Medicine, Tel-Aviv University
Hypothesis
The review discusses the potential involvement of cell-free mediators in cancer immunotherapy.
Conclusion
The use of cell-free mediators for cancer immunotherapy shows promise, but much more research is needed to ensure effective and reproducible therapeutic outcomes.
Supporting Evidence
- Cell-free mediators have been shown to activate immune responses against tumors.
- Prostaglandins are generally thought to inhibit anti-tumor activity, while leukotrienes may enhance it.
- Clinical trials with TNF-a have shown disappointing results, indicating the need for further research.
Takeaway
Scientists are studying how certain substances in the body can help fight cancer, but they still need to learn a lot more before these treatments can be used regularly.
Methodology
The review summarizes various experimental and clinical investigations into the role of cell-free mediators in cancer immunotherapy.
Limitations
The review indicates that many studies have shown limited success and that more clinical trials are needed.
Want to read the original?
Access the complete publication on the publisher's website